Current Issues in Molecular Biology (May 2023)

Anti-Leukemic Effects of <i>Idesia polycarpa</i> Maxim Branch on Human B-Cell Acute Lymphoblastic Leukemia Cells

  • Chan-Seong Kwon,
  • Ji-Eun Lee,
  • Byeol-Eun Jeon,
  • Ye-Rin Woo,
  • Yun-Seo Kim,
  • Jae-Woo Kim,
  • Chae-Jin Park,
  • Seo-Yun Jang,
  • Sang-Woo Kim

DOI
https://doi.org/10.3390/cimb45050257
Journal volume & issue
Vol. 45, no. 5
pp. 4035 – 4049

Abstract

Read online

Patients with pediatric B-cell acute lymphoblastic leukemia (B-ALL) have a high survival rate, yet the prognosis of adults and patients with relapsed/refractory disease is relatively poor. Therefore, it is imperative to develop new therapeutic strategies. Here, we screened 100 plant extracts from South Korean Flora and investigated their anti-leukemic effect using CCRF-SB cells as a B-ALL model. The top cytotoxic extract identified in this screening was the Idesia polycarpa Maxim. branch (IMB), which efficiently inhibited the survival and proliferation of CCRF-SB cells, while having minimal to no impact on normal murine bone marrow cells. Mechanistically, the IMB-induced proapoptotic effect involves the increase of caspase 3/7 activity, which was shown to be associated with the disruption of the mitochondrial membrane potential (MMP) through the reduction in antiapoptotic Bcl-2 family expression. IMB also promoted the differentiation of CCRF-SB cells via the upregulation of the expression of differentiation-related genes, PAX5 and IKZF1. Given that resistance to glucocorticoid (GC) is often found in patients with relapsed/refractory ALL, we investigated whether IMB could restore GC sensitivity. IMB synergized GC to enhance apoptotic rate by increasing GC receptor expression and downmodulating mTOR and MAPK signals in CCRF-SB B-ALL cells. These results suggest that IMB has the potential to be a novel candidate for the treatment of B-ALL.

Keywords